TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01641419
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of saline added to 30 ml of ropivacaine 0.5% solution for nerve block
Study: NCT00066586
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo once daily x 1 year
Study: NCT03337490
Drug: Placebo 0% Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects on Placebo will receive a single dose, 117g, during the study to be applied at baseline.
Study: NCT01105546
Drug: recombinant activated factor VII
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 µg/kg/day i.v.
Study: NCT01105546
Drug: recombinant activated factor VII
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment of bleeding episodes with 270 µg/kg (first/single dose) or 90 µg/kg i.v. every 2-3 hours until bleeding resolution
Study: NCT01689532
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Between sirukumab injections, placebo SC at Weeks 2, 6, and every 4 weeks through Week 52.
Study: NCT00644007
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as a substitute of SK3530 100mg
Study: NCT00644007
Drug: SK3530
Approvals — FDA: no, EMA: no, PMDA: no
Description: SK3530 100 mg
Study: NCT00778193
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet 500mg BID for 8 days
Study: NCT00778193
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 capsule 200mg QD for 8 days
Study: NCT00778193
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule BID for 8 days
Study: NCT04150107
Drug: ORMD-0801 Treatment B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B: 8 mg (8 mg capsule) three times a day (TID) 45-90 minutes before meals
Study: NCT00111007
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 2 tablets bid Study Days 2-19
Study: NCT00040209
Drug: JP 1730
Normalized name: ALCOHOL 70 mL in 100 mL TOPICAL GEL [JP P Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02782858
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly IV repeated dose
Study: NCT00040209
Drug: IV Levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01412294
Drug: Capecitabine, Cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Capecitabine Capecitabine will be administered at 1,000 mg/m2 orally, twice daily (2,000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.~Drug: Cisplatin Cisplatin will be administered at 80 mg/m2 by intravenous infusion on Day 1 of each 21-day treatment cycle.
Study: NCT01565655
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01419405
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50-90 min: TCI 0.6 ng/mL, 100-140 min: 1.2 ng/mL, 150-190 min: TCI 2.4 ng/mL
Study: NCT01419405
Drug: sugar pill, saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: hard capsule, 150 mg, 2 times, 2 days, saline infusion
Study: NCT02709538
Drug: GSP 301 Placebo NS pH 3.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 spray in each nostril twice daily for 52 weeks
Study: NCT02709538
Drug: GSP 301 Placebo NS pH 7.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 spray in each nostril twice daily for 52 weeks
Study: NCT02160041
Drug: BGJ398
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGJ398 was dosed on a flat scale of 125 mg (e.g., 1 x 100 mg and 1 x 25 mg capsules) once daily for the first 21 days of the 28-day cycle (3 weeks on, 1 week off in a cycle). A complete treatment cycle is defined as 28 days.
Study: NCT00540410
Drug: Coarsucam® (artésunate (AS) + amodiaquine (AQ) as fixed dose combination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infants tablets: AS 25/AQ 67,5 mg Toddlers tablets: AS 50/AQ 135 mg Once daily, dose according to bodyweight range Duration of treatment: 3days Children tablets: AS 100/AQ 270 mg
Study: NCT00540410
Drug: Coartem® (arthemether+ lumefantrine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, 20/120 mg, oral route, twice daily, dose according to bodyweight range.~Duration of treatment: 3 days
Study: NCT02059291
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to canakinumab solution for subcutaneous injection
Study: NCT06275633
Drug: Levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Medicine response
Study: NCT01240109
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * propofol group : propofol effect site-TCI 2-4mcg/ml + remifentanil effect site-TCI 2-4ng/ml~* sevoflurane group: sevoflurane end-tidal concentration 0.5-1.0 MAC + remifentanil effect site-TCI 2-4ng/ml
Study: NCT03785223
Drug: Placebo Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: At Week 0 or Week 7, dosing will start at 1 capsule/day for one week, and be titrated to 2 capsules/day for Week 2. The dose may be titrated to 75 mg/day for Week 3 and to 100 mg/day for Week 4 if participants are tolerating their current dose, are experiencing no adverse events, and have not fully responded. By Week 4 or Week 11 no further dose changes will occur.
Study: NCT03614052
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablet 1 tablet per day for 5 days before ureteroscopic treatment of urolithiasis
Study: NCT02161692
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03930615
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was administered as tablets matched to LET or as inactive (saline or dextrose) intravenous infusion.
Study: NCT03670316
Drug: Algorithm Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline was selected as the first line of treatment for patients willing to take a medication twice per day and wanting cessation. Following varenicline, bupropion and then NRT are subsequent options. In terms of preference for NRT, nicotine patches would be the first option followed by lozenge, gum, inhaler, and nasal spray. The order of NRT within the algorithm is based upon patient familiarity and number of clinical trials supporting their use. Combination NRT (e.g., patch and lozenge) or adding NRT to varenicline or bupropion is offered to participants who have made an unsuccessful quit attempt with these medications in the past. If none of these medications are appropriate, then the participant is offered counseling only.
Study: NCT04611152
Drug: KSI-301
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal Injection
Study: NCT01281475
Drug: Levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa/Carbidopa (4:1)~Dosages are based on levodopa.~Subjects randomized to the levodopa arm will receive a levodopa dose of 5 mg/kg/day in the first 2 weeks of the study, a levodopa dose of 10 mg/kg/day in the second 2 weeks of the study, and a levodopa dose of 15 mg/kg/day (up to a maximum of 800 mg per day) for the remaining duration of the study.~Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day.
Study: NCT01281475
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo contains excipients similar to those in the active drug, but it does not contain levodopa or carbidopa.
Study: NCT02490345
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo
Study: NCT00655174
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this study arm will receive capsules that appear identical to those of the two study drugs but will contain no active ingredient.
Study: NCT00470834
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: making placebo
Study: NCT04456998
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching capsule containing placebo
Study: NCT03258515
Drug: AZD6094 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: A potent and selective small molecule mesenchymal epithelial transition (MET) kinase inhibitor with significant antitumor activity.
Study: NCT01096862
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02765009
Drug: diuretics
Normalized name: DIURETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Used to reduce fluid overload as evidenced by weight gain
Study: NCT01688531
Drug: CD0271 0.1%/CD1579 2.5% gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: one application (pea-sized amount according to the labelling) on a half-face, 5 to 7 days for 6 months
Study: NCT01688531
Drug: CD0271 0.1%/CD1579 2.5% gel vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: one application (pea-sized amount according to the labelling) on a half-face, 5 to 7 days for 6 months
Study: NCT02751385
Drug: Microgynon
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00285012
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg (placebo) by mouth twice daily for 12 weeks (first week is up titration schedule---0.5mg once daily for 3 days, 0.5mg twice daily for 4 days)
Study: NCT02509117
Drug: Placebo single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched Placebo solution/suspension administered as single dose.
Study: NCT02509117
Drug: Placebo multiple dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched Placebo (solution/suspension)administered daily for 14 consecutive days.
Study: NCT01419197
Drug: Treatment of physician's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment of physician's choice (TPC) was a protocol-specified approved or standard of care therapy or combination of therapies, based on frequently used regimens for late-line HER2-positive metastatic breast cancer treatment after receipt of both trastuzumab- and lapatinib-containing regimens. The therapies included single-agent chemotherapy, single-agent (e.g., tamoxifen or aromatase inhibitor) or dual-agent (e.g., aromatase inhibitor with luteinizing hormone releasing hormone \[LHRH\] agonist) hormonal therapy for hormone receptor positive-disease, and HER2-directed therapy.~Participants who had documented progressive disease (PD) were eligible to switch treatment to receive trastuzumab emtansine 3.6 mg/kg. Participants who switched treatment remained on trastuzumab emtansine treatment until another PD event or unmanageable toxicity.~The formulation, storage, and preparation of all TPC were as per the appropriate package insert or national prescribing information.
Study: NCT02366884
Drug: Anti-Bacterial Agents
Normalized name: INVESTIGATIONAL ANTI-BACTERIAL DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline, Paramomycin, Clarithromycin, Clindamycin, Dapsone, Miltefosine
Study: NCT02366884
Drug: Anti-Fungal Agents
Normalized name: Aardora Anti-Fungal Maximum Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole, Amphotericin B liposomal, Fluconazole, Terbinafine, Voriconazole
Study: NCT02366884
Drug: Anti-Protozoal Agents
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitazoxanide, Chloroquine, Albendazole, Ivermectin, Mebendazole, Metronidazole, Praziquantel, Levamisole
Study: NCT02352285
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Start with 15mg to titrate upwards to 30mg to 60mg, once a daily
Study: NCT02175927
Drug: Tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: antibiotic of classical quadruple therapy
Study: NCT02873195
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02838329
Drug: Ropivicaine
Normalized name: Ropivicaine-Sufentanil Citrate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01685151
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00125528
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo bid
Study: NCT02874144
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: looks like AZ compound, made by same company, double blind. 40 mg three times daily po for 12 weeks
Study: NCT00003497
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
Study: NCT01269242
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: bindarit-matching placebo tablets for 6 months.
Study: NCT03564704
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CTX will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.
Study: NCT03564704
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate will be added to Consolidation-Module of PDT-ALL-LBL protocol.
Study: NCT03564704
Drug: 6-mercaptopurine.
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mercaptopurine will be added to Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.
Study: NCT01461109
Drug: [18F] CFPyPB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive a bolus injection targeted to be 5 mCi and not to exceed 5.5 mCi (not \>10% of 5 mCi limit) of \[18F\]CFPyPB or 5 μg of CFPyPB (whichever is greatest).
Study: NCT00666484
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00666484
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00666484
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04109885
Drug: Paracervical injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mL of 0.5% bupivacaine will be will be injected bilaterally in the paraspinal musculature of the cervical spine.
Study: NCT01578850
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: etanercept placebo once weekly + methotrexate with or without other DMARDs
Study: NCT01232803
Drug: 2% N-9 gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entire contents of an applicator will be inserted rectally, for a total of 8 doses.
Study: NCT01232803
Drug: HEC Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entire contents of an applicator will be inserted rectally, for a total of 8 doses.
Study: NCT01318005
Drug: Oral Contraceptive: Ortho-Novum® 1/35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Contraceptive: Ortho-Novum® 1/35, pill, 2-3 mos, daily.
Study: NCT01318005
Drug: Oral Contraceptive: Ovcon® 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Contraceptive: Ovcon® 35, pill, 2-3 mos, daily.
Study: NCT01318005
Drug: Oral Contraceptive: Microgestin Fe® 1/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Contraceptive: Microgestin Fe® 1/20, pill, 2-3 mos, daily.
Study: NCT00637988
Drug: Rofecoxib
Normalized name: Rofecoxib
DrugBank: Rofecoxib (DB00533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg once daily
Study: NCT03849625
Drug: aspirin, NSAIDs, paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perform skin test and/or provocation test with aspirin, paracetmol, or suspected NSAIDs in questionable cases
Study: NCT00464971
Drug: estradiol, 25 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04278872
Drug: SJX-653
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered orally once daily
Study: NCT04278872
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered orally once daily
Study: NCT02042573
Drug: SSRI (SEROPLEX ou ZOLOFT)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00967954
Drug: antiandrogen therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02500940
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Neoadjuvant chemotherapy regimen with Fluorouracil
Study: NCT02500940
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Neoadjuvant chemotherapy regimen with Leucovorin
Study: NCT02183168
Drug: Meloxicam suppository
Normalized name: meloxicam Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02183168
Drug: Meloxicam tablet
Normalized name: Meloxicam Tablets
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02183168
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00576940
Drug: Reconvan
Approvals — FDA: no, EMA: no, PMDA: no
Description: isocaloric, immunomodulating entral diet
Study: NCT00576940
Drug: Peptisorb
Approvals — FDA: no, EMA: no, PMDA: no
Description: isocaloric, isopeptic standard diet
Study: NCT01642862
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of pharmacokinetic parameters of different formulations (liquid vs tablet) and doses (20 or 40 mg) of simvastatin after single oral administration of the drug
Study: NCT00241059
Drug: Enteric-Coated Mycophenolate Sodium (EC-MPS)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04423107
Drug: Acetaminophen, Ibuprofen, Oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (Tylenol) 15 mg/kg q6h, Ibuprofen q6h, and Oxycodone 0.1 mg/kg q6h
Study: NCT03371095
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Use of cyclophosphamide
Study: NCT00006050
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00006050
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00006050
Drug: isolated perfusion
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00006050
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00685009
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill daily
Study: NCT02335814
Drug: FLX925
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00160667
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral dose of two equal intakes.
Study: NCT00123253
Drug: TH9507
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03456882
Drug: RNS60
Normalized name: Ronasin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline plus oxigen in nanobubble
Study: NCT03083457
Drug: General anesthetic
Normalized name: General anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia with a standard protocol
Study: NCT00239135
Drug: PEP005
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03083457
Drug: Fluid administration
Normalized name: Fluid Administration Set
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-5 ml/kg of balanced crystalloids will be administered throughout the whole surgical procedure
Study: NCT00118495
Drug: Non-prescription Zestra(TM): patented formulation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03772288
Drug: NKTR-214
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion.
Study: NCT02872285
Drug: Drug: LYC-30937-EC
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02872285
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01407380
Drug: PWT33597 mesylate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: PWT33597 taken orally daily for 28 consecutive days in 28 day cycle
Study: NCT00534599
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00554710
Drug: methylprednisolone or budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: methylprednisolone 32 mg followed by taper or budesonide 9 mg/day followed by taper
Study: NCT02553356
Drug: PT2385
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03629275
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham surgical comparator includes stereotactic surgery and a partial thickness burr hole drilled into the skull. No injection of any kind is made into the brain, and no other intervention is given.
Study: NCT02392377
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02392377
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00985127
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered daily for 21 days
Study: NCT01760785
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses will be titrated over the first four days of study in the same manner as the active study drug. After titration, the research pharmacy may increase the dose by 1 tablet per day, in the same fashion that the active drug may be adjusted, so that the participant and clinical team remain blinded to the drug assignment. The research pharmacy may also reduce the daily dosage back down by one tablet per day for the same reason.
Study: NCT01349049
Drug: PLX3397
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximum Tolerated Dose of PLX3397 will be administered orally, twice daily.
Study: NCT01349049
Drug: PLX3397
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug product is available in capsule form, to be taken orally.
Study: NCT00807859
Drug: AMG 386 30 mg/kg, Capecitabine and Lapatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 386 30 mg/kg IV QW, capecitabine 2000 mg/m2 divided into 2 doses given PO Q12 hrs, days 1-14 every 21 days, lapatinib 1250 mg PO QD
Study: NCT04330729
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Se arm description